The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; Merck Sharp & Dohme; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Novartis
 
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer
KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab.
 
Natasha B. Leighl
No Relationships to Disclose
 
Matthew David Hellmann
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Janssen; Merck; Novartis
Research Funding - Bristol-Myers Squibb; Genentech/Roche
 
Rina Hui
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer
Consulting or Advisory Role - AstraZeneca; Merck Sharp & Dohme; Novartis; Pfizer
 
Enric Carcereny Costa
No Relationships to Disclose
 
Enriqueta Felip
No Relationships to Disclose
 
Myung-Ju Ahn
No Relationships to Disclose
 
Joseph Paul Eder
Honoraria - Merck; Nektar
Research Funding - AstraZeneca (Inst)
 
Ani Sarkis Balmanoukian
Speakers' Bureau - Bristol-Myers Squibb; Genentech; Merck
 
Charu Aggarwal
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; Lilly
Speakers' Bureau - Genentech (I); Novartis (I); Pfizer (I)
Research Funding - Genentech/Roche (Inst); Incyte (Inst); Macrogenics (Inst); Millennium (Inst); Nektar (Inst)
 
Leora Horn
Honoraria - Biodesix
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Lilly; Merck; Xcovery
Research Funding - AstraZeneca (Inst)
 
Amita Patnaik
Consulting or Advisory Role - Bayer
Research Funding - Abbvie; Aeglea Biotherapeutics; Alexion Pharmaceuticals; Amgen; Asana Biosciences; Ascentage Pharma Group; Astex Pharmaceuticals; AVEO (Inst); Bayer; Bayer (Inst); Calithera Biosciences; Celgene (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Endocyte (Inst); Five Prime Therapeutics (Inst); Formation Biologics (Inst); Forty Seven; Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jiangsu Hengrui Medicine; Jiangsu Hengrui Medicine (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Merck Sharp & Dohme; Novartis; OncoMed; Pfizer (Inst); Plexxikon; Plexxikon (Inst); Regeneron (Inst); Symphony Evolution (Inst); TaiRx, Inc. (Inst); Tesaro (Inst); Tesaro (Inst); Teva (Inst); Upsher-Smith; Zymeworks (Inst)
 
Matthew A. Gubens
Consulting or Advisory Role - ARIAD; Boehringer Ingelheim; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; Nektar; Pfizer
Research Funding - Abbvie (Inst); Celgene (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); OncoMed (Inst)
Travel, Accommodations, Expenses - Celgene; Genentech/Roche
 
Suresh S. Ramalingam
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Merck; Novartis
Travel, Accommodations, Expenses - AstraZeneca; EMD Serono; Pfizer
 
Gregory M. Lubiniecki
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Jin Zhang
Employment - Merck
Travel, Accommodations, Expenses - Merck
 
Bilal Piperdi
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Edward B. Garon
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)